Independent audits and a Platinum CyberVadis rating demonstrate the rigor, resilience, and maturity of the OPUS platform-the industry's secure, audit-ready foundation for digitalization, partner ...
Introduction Colonic diverticulosis is the most common structural abnormality of the colon in developed countries, with an increasing global prevalence. Approximately 20–25% of affected individuals ...
AZoLifeSciences on MSN
CRISPR for Christmas? The year’s biggest gene editing breakthroughs, unwrapped
In 2025, CRISPR advanced gene editing with safe, effective therapies and AI tools, marking a shift towards real-world ...
Revised version global guidelines on diverticular disease of the colon: the Fiesole Consensus report
Introduction Colonic diverticulosis is the most common structural abnormality of the colon in developed countries, with an increasing global prevalence. Approximately 20–25% of affected individuals ...
This article explores the US and EU compliance requirements to ensure patient safety for GMP ancillary materials in cell and ...
A new set of proposed statewide graduation requirements has lawmakers and educators asking questions about continued reliance ...
Iron Software, a leading developer of .NET libraries and tools, today announced an $USD18,000 donation to Warm Heart Worldwide/Biochar Life to fund 50 biochar kilns in northern Thailand. This ...
An Education Cannot Wait-funded, Norwegian Refugee Council and Save the Children-supported holistic education programme is ...
Families in the Marion Homeschool Assistance Program share choosing their own curriculum, flexibility in their schedule and ...
Objectives Although menstrual cups have a long history and numerous benefits, many women of reproductive age remain unaware. This study assessed the knowledge, attitude and use regarding menstrual ...
Evolution and innovation are critical to the field of life sciences, with each year bringing new challenges and breakthroughs. This holds especially true in the built environment — the labs, offices, ...
2024 was pivotal for UK Life Sciences’ venture funding landscape. Softening macro and geopolitical conditions saw activity rebound, setting the stage for an upwards trajectory in 2025. Our recent Life ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback